- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00300755
Undersøgelse, der evaluerer pantoprazol hos børn med gastroøsofageal reflukssygdom (GERD)
En multicenter, randomiseret, dobbeltblind undersøgelse af de kliniske resultater, sikkerhed og tolerabilitet af flere doser af pantoprazolnatrium enterisk coated sfæroider hos børn i alderen 1 til 5 med endoskopisk bevist symptomatisk gastroøsofageal reflukssygdom (GERD)
To evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
-
London, Ontario, Canada, N6A 4G5
-
Ottawa, Ontario, Canada, K1H 8L1
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
-
Montreal, Quebec, Canada, H3T 1C5
-
-
-
-
Alabama
-
Mobile, Alabama, Forenede Stater, 36604
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85016
-
-
California
-
Oakland, California, Forenede Stater, 94609
-
Orange, California, Forenede Stater, 92868
-
Sacramento, California, Forenede Stater, 95819
-
San Diego, California, Forenede Stater, 92103
-
-
Delaware
-
Wilmington, Delaware, Forenede Stater, 19803
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20010
-
-
Florida
-
Gainesville, Florida, Forenede Stater, 32610
-
Jacksonville, Florida, Forenede Stater, 32207
-
Miami, Florida, Forenede Stater, 33101
-
Orlando, Florida, Forenede Stater, 32806
-
Pensacola, Florida, Forenede Stater, 32504
-
-
Illinois
-
Peoria, Illinois, Forenede Stater, 61603
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40536
-
Louisville, Kentucky, Forenede Stater, 40202
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
-
Boston, Massachusetts, Forenede Stater, 02115
-
-
Michigan
-
Flint, Michigan, Forenede Stater, 48503
-
Southfield, Michigan, Forenede Stater, 48075
-
-
Mississippi
-
Jackson, Mississippi, Forenede Stater, 39216
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68105
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89102
-
-
New Jersey
-
Egg Harbor, New Jersey, Forenede Stater, 08234
-
Morristown, New Jersey, Forenede Stater, 07962
-
-
New York
-
Buffalo, New York, Forenede Stater, 14222
-
New York, New York, Forenede Stater, 10032
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
-
-
Pennsylvania
-
Danville, Pennsylvania, Forenede Stater, 17822-1320
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
-
Temple, Texas, Forenede Stater, 76508
-
-
Virginia
-
Norfolk, Virginia, Forenede Stater, 23507
-
-
West Virginia
-
Charleston, West Virginia, Forenede Stater, 25304
-
Huntington, West Virginia, Forenede Stater, 25701-3655
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53215
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Ability to undergo endoscopy with required biopsy
- Ages 1 through 5 years
- Endoscopically confirmed GERD by positive endoscopic evidence of reflux related esophagitis or positive histologic evidence of esophagitis consistent with GERD Other inclusions apply.
Exclusion Criteria:
- History or presence of upper gastrointestinal anatomic or motor disorders
- Known current or active cow's milk allergy
- Malignancy
- Other exclusions apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: 1
Low Dose Pantoprazole (Approximately 0.3 mg/kg) |
Pediatric spheroids administered once daily for 8 weeks. |
|
Aktiv komparator: 2
Medium Dose Pantoprazole (Approximately 0.6 mg/kg) |
Pediatric spheroids administered once daily for 8 weeks. |
|
Aktiv komparator: 3
High Dose Pantoprazole (Approximately 1.2 mg/kg) |
Pediatric spheroids administered once daily for 8 weeks. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Weekly Gastroesophageal Reflux Disease (GERD) Symptom Scores (WGSS)
Tidsramme: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, and Final Week
|
Weekly GERD symptom score (WGSS) is the sum of 5 selected individual weekly GERD mean frequency scores: vomiting/regurgitation, choking/gagging, refusal to eat, difficulty swallowing and abdominal/belly pain. Symptoms were assessed using a parent-administered questionnaire. The score for each individual symptom ranged from 0 (no symptoms) to 3 (highest frequency of symptoms), giving a WGSS range of 0-15. Change = score at week of assessment minus baseline score. Final Week was defined as the last 7 days of symptom scores collected during the treatment period. |
Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, and Final Week
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Individual Weekly Mean Frequency Score for Each Gastroesophageal Reflux Disease (GERD) Symptom Score From Baseline to Final Week
Tidsramme: Baseline and 8 weeks
|
Selected symptoms of GERD were assessed using a parent-administered questionnaire. The score for each symptom ranged from 0 (no symptom) to 3 (highest frequency of symptom), The weekly mean score was the sum of daily scores that week, divided by the number of days with scores for that week. Change = final week score minus baseline score. Final week was defined as the last 7 days of scores collected in the treatment period. |
Baseline and 8 weeks
|
|
Change in Individual Weekly Mean Score For Each Respiratory Symptom From Baseline
Tidsramme: Baseline and 8 weeks
|
Individual respiratory symptoms weekly score was calculated as the average score / number of events for a patient in the corresponding week if the patient answered a question ≥3 times that week. Change = final week score minus baseline score. Final week was defined as the last 7 days of scores collected in the treatment period. |
Baseline and 8 weeks
|
|
Number of Patients With "Healed" Erosive Esophagitis (EE) at End of Study
Tidsramme: 8 weeks
|
Healed EE was defined as a modified Hetzel-Dent (HD) score <2 on endoscopy at end of study. HD is a standardized rating scale for grading esophageal damage and severity of gastroesophageal reflux disease (GERD). HD score ranges from 0 (normal mucosa) to 4 (deep peptic ulceration). |
8 weeks
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Studieleder: Medical Monitor, Wyeth is now a wholly owned subsidiary of Pfizer
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 3001B3-328
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .